Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.43 |
| ▸ | CHRNB2 | P17787 | 4/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.42 |
| ▸ | CHRNB4 | P30926 | 3/20 | 0.42 |
| ▸ | CHRNA3 | P32297 | 3/20 | 0.42 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.40 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | NAMPT | P43490 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22001900 | 1.00 | NR1H2 (0.43) | NR1H2CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL22001901 | 1.00 | NR1H2 (0.43) | NR1H2CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL928993 | 0.86 | CHRNB2 (0.54) | NR1H2CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL3241502 | 0.83 | CHRNB2 (0.56) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL25045229 | 0.81 | CHRNB2 (0.48) | NR1H2CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL22169156 | 0.80 | NR1H2 (0.50) | NR1H2CHRNB2CHRNA4CHRNA3KDM4E | |
| SCHEMBL608991 | 0.80 | NR1H2 (0.50) | NR1H2CHRNB2CHRNA4CHRNA3KDM4E | |
| SCHEMBL24884312 | 0.80 | NR1H2 (0.50) | NR1H2CHRNB2CHRNA4CHRNA3KDM4E | |
| SCHEMBL400513 | 0.80 | NR1H2 (0.50) | NR1H2CHRNB2CHRNA4CHRNA3KDM4E | |
| SCHEMBL3236313 | 0.80 | CHRNB2 (0.43) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11208422-B2 | Substituted bridged diazepane derivatives and use thereof as TASK-1 and TASK-3 inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-12-28 | — | — | US | disclosed |
| WO-2021067606-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. (US) | 2021-04-08 | — | — | WO | disclosed |
| US-20200140461-A1 | SUBSTITUTED BRIDGED DIAZEPANE DERIVATIVES AND USE THEREOF AS TASK-1 AND TASK-3 INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-05-07 | — | — | US | disclosed |
| US-6153608-A | Isoquinoline derivatives and drugs | NIPPON SHINYAKU CO., LTD. (JP) | 2000-11-28 | — | — | US | disclosed |
| EP-0885888-A1 | ISOQUINOLINE DERIVATIVES AND DRUGS | NIPPON SHINYAKU COMPANY, LIMITED (JP) | 1998-12-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11208422-B2 | Substituted bridged diazepane derivatives and use thereof as TASK-1 and TASK-3 inhibitors | BET1, HRH1, GRIN1 | NR1H2 867/4885CHRNB2 356/4885CHRNA4 179/4885 |
| US-20200140461-A1 | SUBSTITUTED BRIDGED DIAZEPANE DERIVATIVES AND USE THEREOF AS TASK-1 AND TASK-3 INHIBITORS | GRIN1, BET1, HRH1 | NR1H2 742/4885CHRNB2 276/4885CHRNA4 148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.